These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

551 related items for PubMed ID: 23294310

  • 1. The potential of HDAC inhibitors as cognitive enhancers.
    Gräff J, Tsai LH.
    Annu Rev Pharmacol Toxicol; 2013; 53():311-30. PubMed ID: 23294310
    [Abstract] [Full Text] [Related]

  • 2. Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior.
    Pal D, Sahu P, Mishra AK, Hagelgans A, Sukocheva O.
    Curr Drug Targets; 2023; 24(9):728-750. PubMed ID: 36475351
    [Abstract] [Full Text] [Related]

  • 3. Targeting the correct HDAC(s) to treat cognitive disorders.
    Fischer A, Sananbenesi F, Mungenast A, Tsai LH.
    Trends Pharmacol Sci; 2010 Dec; 31(12):605-17. PubMed ID: 20980063
    [Abstract] [Full Text] [Related]

  • 4. HDAC modulation and cell death in the clinic.
    Dell'Aversana C, Lepore I, Altucci L.
    Exp Cell Res; 2012 Jul 01; 318(11):1229-44. PubMed ID: 22336671
    [Abstract] [Full Text] [Related]

  • 5. Epigenetic histone acetylation and deacetylation mechanisms in experimental models of neurodegenerative disorders.
    Konsoula Z, Barile FA.
    J Pharmacol Toxicol Methods; 2012 Jul 01; 66(3):215-20. PubMed ID: 22902970
    [Abstract] [Full Text] [Related]

  • 6. Targeting histone deacetylase in thyroid cancer.
    Russo D, Durante C, Bulotta S, Puppin C, Puxeddu E, Filetti S, Damante G.
    Expert Opin Ther Targets; 2013 Feb 01; 17(2):179-93. PubMed ID: 23234477
    [Abstract] [Full Text] [Related]

  • 7. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity.
    Fass DM, Reis SA, Ghosh B, Hennig KM, Joseph NF, Zhao WN, Nieland TJ, Guan JS, Kuhnle CE, Tang W, Barker DD, Mazitschek R, Schreiber SL, Tsai LH, Haggarty SJ.
    Neuropharmacology; 2013 Jan 01; 64():81-96. PubMed ID: 22771460
    [Abstract] [Full Text] [Related]

  • 8. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
    Bush EW, McKinsey TA.
    Circ Res; 2010 Feb 05; 106(2):272-84. PubMed ID: 20133912
    [Abstract] [Full Text] [Related]

  • 9. Cognitive function in health and disease: the role of epigenetic mechanisms.
    Mungenast AE, Tsai LH.
    Neurodegener Dis; 2012 Feb 05; 10(1-4):191-4. PubMed ID: 22301371
    [Abstract] [Full Text] [Related]

  • 10. Histone acetylation: molecular mnemonics on the chromatin.
    Gräff J, Tsai LH.
    Nat Rev Neurosci; 2013 Feb 05; 14(2):97-111. PubMed ID: 23324667
    [Abstract] [Full Text] [Related]

  • 11. Epigenetic modifications in the nervous system and their impact upon cognitive impairments.
    Rudenko A, Tsai LH.
    Neuropharmacology; 2014 May 05; 80():70-82. PubMed ID: 24495398
    [Abstract] [Full Text] [Related]

  • 12. Histone deacetylase inhibitors in cancer therapy.
    Lane AA, Chabner BA.
    J Clin Oncol; 2009 Nov 10; 27(32):5459-68. PubMed ID: 19826124
    [Abstract] [Full Text] [Related]

  • 13. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
    Chen PJ, Huang C, Meng XM, Li J.
    Biochimie; 2015 Sep 10; 116():61-9. PubMed ID: 26116886
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic potential of isoform selective HDAC inhibitors for the treatment of schizophrenia.
    Weïwer M, Lewis MC, Wagner FF, Holson EB.
    Future Med Chem; 2013 Sep 10; 5(13):1491-508. PubMed ID: 24024943
    [Abstract] [Full Text] [Related]

  • 15. Epigenetic modifications by inhibiting histone deacetylases reverse memory impairment in insulin resistance induced cognitive deficit in mice.
    Sharma S, Taliyan R.
    Neuropharmacology; 2016 Jun 10; 105():285-297. PubMed ID: 26805421
    [Abstract] [Full Text] [Related]

  • 16. Human neuronal cells: epigenetic aspects.
    Kukucka J, Wyllie T, Read J, Mahoney L, Suphioglu C.
    Biomol Concepts; 2013 Aug 10; 4(4):319-33. PubMed ID: 25436583
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of histone deacetylases.
    Huang Y, Shaw PG, Davidson NE.
    Methods Mol Biol; 2011 Aug 10; 791():297-311. PubMed ID: 21913088
    [Abstract] [Full Text] [Related]

  • 18. [EPIGENETIC ENZYMES AS THERAPEUTIC TARGETS FOR TREATING BRAIN DISORDERS].
    Gomazkov OA.
    Eksp Klin Farmakol; 2015 Aug 10; 78(11):35-44. PubMed ID: 27017704
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA.
    Annu Rev Pharmacol Toxicol; 2012 Aug 10; 52():303-19. PubMed ID: 21942627
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.